BACKGROUND: Renal ischemia-reperfusion (I/R) injury, as a common and clinically important problem, starts with direct damage caused by chemokines and inflammatory cytokines, which is aggravated by specific and nonspecific immune reactions. Recently, IL-17A has been considered to be in a uniquely powerful position between adaptive and innate immunity. The present study investigated the role of IL-17A in renal I/R injury in mice. METHODS: We measured the time-course of changes in plasma and renal IL-17A levels using a murine model of renal I/R injury. Then, the protective effect of monoclonal anti-IL-17A antibody, given intravenously at 30 min before or after renal I/R operation, on renal I/R injury was investigated. In addition, the levels of plasma and renal pro- and anti-inflammatory cytokines and chemokines were assessed. RESULTS: IL-17A was significantly increased in plasma and kidneys after renal I/R injury in mice. Furthermore, intravenous administration of neutralizing monoclonal anti-IL-17A antibody attenuated renal I/R injury by evaluating renal function and histopathology. In addition, administration of anti-IL-17A antibody substantially reduced the plasma and renal levels of many pro-inflammatory mediators (TNF-α, IL-6, high-mobility group box 1 (HMGB1), IL-1β, IL-17A, macrophage inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1), as well as increased the plasma and renal levels of anti-inflammatory cytokines IL-10 and transforming growth factor β (TGF-β). CONCLUSION: The above data suggest that IL-17A has a detrimental effect on renal I/R injury via facilitating the production of pro-inflammatory cytokines and chemokines as well as hampering the production of anti-inflammatory cytokines. Crown
BACKGROUND: Renal ischemia-reperfusion (I/R) injury, as a common and clinically important problem, starts with direct damage caused by chemokines and inflammatory cytokines, which is aggravated by specific and nonspecific immune reactions. Recently, IL-17A has been considered to be in a uniquely powerful position between adaptive and innate immunity. The present study investigated the role of IL-17A in renal I/R injury in mice. METHODS: We measured the time-course of changes in plasma and renal IL-17A levels using a murine model of renal I/R injury. Then, the protective effect of monoclonal anti-IL-17A antibody, given intravenously at 30 min before or after renal I/R operation, on renal I/R injury was investigated. In addition, the levels of plasma and renal pro- and anti-inflammatory cytokines and chemokines were assessed. RESULTS:IL-17A was significantly increased in plasma and kidneys after renal I/R injury in mice. Furthermore, intravenous administration of neutralizing monoclonal anti-IL-17A antibody attenuated renal I/R injury by evaluating renal function and histopathology. In addition, administration of anti-IL-17A antibody substantially reduced the plasma and renal levels of many pro-inflammatory mediators (TNF-α, IL-6, high-mobility group box 1 (HMGB1), IL-1β, IL-17A, macrophage inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1), as well as increased the plasma and renal levels of anti-inflammatory cytokines IL-10 and transforming growth factor β (TGF-β). CONCLUSION: The above data suggest that IL-17A has a detrimental effect on renal I/R injury via facilitating the production of pro-inflammatory cytokines and chemokines as well as hampering the production of anti-inflammatory cytokines. Crown
Authors: Mayya Geha; Maria G Tsokos; Robin E Bosse; Tatyana Sannikova; Yoichiro Iwakura; Jurandir J Dalle Lucca; Rene De Waal Malefyt; George C Tsokos Journal: J Immunol Date: 2017-09-06 Impact factor: 5.422
Authors: Dickson W L Wong; Wai Han Yiu; Kam Wa Chan; Ye Li; Bin Li; Sarah W Y Lok; Makoto M Taketo; Peter Igarashi; Loretta Y Y Chan; Joseph C K Leung; Kar Neng Lai; Sydney C W Tang Journal: Kidney Int Date: 2018-03-28 Impact factor: 10.612
Authors: Macarena Orejudo; Raul R Rodrigues-Diez; Raquel Rodrigues-Diez; Ana Garcia-Redondo; Laura Santos-Sánchez; Javier Rández-Garbayo; Pablo Cannata-Ortiz; Adrian M Ramos; Alberto Ortiz; Rafael Selgas; Sergio Mezzano; Carolina Lavoz; Marta Ruiz-Ortega Journal: Front Pharmacol Date: 2019-09-13 Impact factor: 5.810